# SYMFI
> **NDA022142** · New Drug Application · Sponsor: MYLAN LABS LTD · Approved 2018-03-22
## Drug
- **FDA Application Number:** NDA022142
- **Application type:** New Drug Application
- **Brand name:** SYMFI
- **Generic name:** EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE
- **Active ingredients:** EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE
- **Dosage form:** TABLET
- **Route:** ORAL
- **Marketing status:** Prescription
- **Sponsor:** MYLAN LABS LTD
- **Manufacturer:** Viatris Specialty LLC
- **First approval:** 2018-03-22
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022142)
---
*AI Analytics · CC0 1.0*